Advertisement
UK markets close in 8 hours 15 minutes
  • FTSE 100

    8,029.34
    +5.47 (+0.07%)
     
  • FTSE 250

    19,597.25
    -2.14 (-0.01%)
     
  • AIM

    749.58
    +0.40 (+0.05%)
     
  • GBP/EUR

    1.1588
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.2339
    -0.0011 (-0.09%)
     
  • Bitcoin GBP

    53,839.51
    +91.40 (+0.17%)
     
  • CMC Crypto 200

    1,397.86
    -16.90 (-1.19%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,315.30
    -31.10 (-1.33%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,795.42
    +283.73 (+1.72%)
     
  • DAX

    17,871.42
    +10.62 (+0.06%)
     
  • CAC 40

    8,040.36
    0.00 (0.00%)
     

How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17

In 3Q17, United Therapeutics' (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.